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Abstract 
Adalimumab is a fully human monoclonal anti-tumor necrosis factor-α agent that is 
approved for the treatment of Crohn’s disease. It has a good safety profile, injection site 
reactions being the most common adverse effect. We report a case of a 54-year-old 
woman with a 30-year history of Crohn’s disease who developed achromic patches on 
the trunk and upper extremities after initiating treatment with adalimumab. Cutaneous 
biopsy confirmed diagnosis of vitiligo and laboratory testing ruled out thyroid disease. 
Concomitant occurrence of vitiligo and inflammatory bowel disease, although rare, has 
been described. A common autoimmune basis could explain this fact. Moreover, multiple 
cutaneous adverse effects have been described in the literature secondary to biologic 
treatments, including vitiligo. In this report, we discuss the possibility of vitiligo as 
secondary to adalimumab treatment or as an association between both diseases. 
 
Introduction 
Tumor necrosis factor-α antagonists (anti-TNFα) are approved for the treatment of 
dermatologic, rheumatologic and gastroenterologic conditions. Although these drugs 
have been shown to have a good safety profile, numerous adverse effects have been 
described, including cutaneous side effects
 [1].   
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Case Report 
We report a case of a 54-year-old woman with a 30-year history of Crohn’s disease with perianal 
involvement who was unresponsive to multiple antibacterial drugs. Different immunosuppressive 
agents (6-mercaptopurin, azathioprine and methotrexate) were also attempted, but they had to be 
stopped due to adverse effects. Treatment with adalimumab was then initiated with standard doses 
(initial dose: 160 mg in week 0, 80 mg in week 2, and 40 mg every 2 weeks thereafter) resulting in 
disease control. Eight months after initiation of the therapy, the patient developed different sized 
achromic patches localized on the ventral aspect of her upper extremities and trunk (fig. 1). Cutaneous 
biopsy showed no melanocytes in the basal layer of the epidermis and no other changes; thus, the 
diagnosis of vitiligo was made (fig. 1). Laboratory tests did not find any autoimmune disorders, such as 
thyroid dysfunction, which are sometimes associated with the diagnosis of vitiligo. Adalimumab was 
not stopped. 
Discussion 
Adalimumab is a fully human monoclonal anti-TNFα that is approved for the 
treatment of Crohn’s disease. Overall, adalimumab is well tolerated. The most common 
side effect is injection site reaction. Other cutaneous adverse effects have been described 
secondary to adalimumab treatment and other anti-TNFα drugs, including immune-
mediated skin conditions [1, 2]. The most reported events are skin infections, 
toxicodermias, eczema, pruritus, psoriasis vulgaris and psoriasis-like lesions, 
leukocytoclastic vasculitis, lupus-like syndrome and cutaneous lupus. To the best of our 
knowledge, only 4 case reports on vitiligo have been described following biologic 
treatments [2–4]. Three patients developed vitiligo secondary to infliximab treatment [2, 
4]. The mechanism of development has been supposed to be the same as in case of the 
lupus-like syndrome [4]. Smith et al. [3] reported 1 patient who developed vitiligo after 
resolution of psoriatic plaques during treatment with adalimumab. However, the authors 
considered the onset of vitiligo to be more related to the Koebner phenomenon rather 
than being a result of biologic treatment. 
In contrast, the use of anti-TNFα agents has been proposed as a possible therapy for 
vitiligo, as TNFα has shown to play an important role in this disease [5]. Overexpression 
of TNFα has been found in lesional skin compared to healthy skin. Moreover, case reports 
on vitiligo successfully treated with infliximab have been described [6]. 
Vitiligo is widely considered to have an autoimmune basis. Accordingly, the increased 
associated occurrence of other autoimmune disorders, mainly thyroid disease, supports 
this theory [7]. Concomitant occurrence with inflammatory bowel disease has been rarely 
reported [8]. This fact is usually explained to be due to immunologic mechanisms, but 
whether the association is significant or merely due to chance is an open question. 
In our case, doubt exists about whether vitiligo is secondary to the treatment with 
adalimumab or, on the contrary, whether it develops as an association between 2 
autoimmune disorders. The long evolution time of the bowel disease, the abrupt onset, 
the rapid generalization of cutaneous lesions, and the temporal relationship with 
initiation of the biologic treatment support the first possibility. Thus, our case seems to be 
the first reported case of vitiligo secondary to the treatment with adalimumab, if we agree 
that the case described by Smith et al. [3] was not related to adalimumab. 
In conclusion, cutaneous adverse effects of anti-TNFα agents are frequent. Therefore, 
dermatologists should be familiarized with them, both for a better management of these  
Case Rep Dermatol 2011;3:28–31 
DOI: 10.1159/000324619 
Published online: 
February 5, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
30
drugs in our field and for recognizing those effects in patients treated with the same 
agents in other specialties. This is probably the first reported case of vitiligo secondary to 
the treatment with adalimumab. 
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Fig. 1. Achromic patches of different sizes and poorly-defined limits, localized on the trunk and ventral 
aspect of the patient’s upper extremities (a–c); absence of melanocytes in the basal layer of epidermis 
[IHQ; HMB-45 ×200] (d). 
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